IP Verse

Pharmaceutical Composition, Methods For Treating And Uses Thereof

Patent No. EP4000608 (titled "Pharmaceutical Composition, Methods For Treating And Uses Thereof") was filed by Boehringer Ingelheim on Apr 16, 2014. The application was issued on Dec 3, 2025.

Patent Summary

Empagliflozin is used in a method for treating chronic kidney disease (CKD) by administration to a patient, optionally in combination with other therapeutic substances such as RAAS inhibitors (direct renin inhibitors, ACE inhibitors, or ARBs) or antidiabetic agents (e.g., metformin, linagliptin). The method targets patients with stage 2, 3, or 4 CKD, or those with microalbuminuria or macroalbuminuria. Patients may further include those with prediabetes, type 1 or type 2 diabetes mellitus, obesity-related glomerulopathy, perihilar focal-segmental glomerulosclerosis, or IgA nephropathy. The treatment aims to prevent, protect against, or delay CKD progression, including progression to end-stage renal disease, renal death, new-onset albuminuria, or sustained eGFR loss of ≥ 50%. Empagliflozin may be administered orally in total daily amounts of 10 mg or 25 mg.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BARDEHLE PAGENBERGSep 2, 2026BARDEHLE PAGENBERG SL
POLPHARMASep 2, 2026ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP4000608

BOEHRINGER INGELHEIM
Application Number
EP21212183A
Filing Date
Apr 16, 2014
Status
Granted And Under Opposition
Oct 31, 2025
Publication Date
Dec 3, 2025
External Links
Slate, Register , Google Patents